Results
Filtros
Cannabis: RDC 327 Review May Enhance Safety for Dentists in 2026
CFO supports dentists among authorized professionals to prescribe safely and with quality
RDC 327 review rapporteur bids farewell to Anvisa this Friday (19).
Rômison Rodrigues Mota leaves the position after a request for review delays the norm's vote; the topic will return to the regulatory agenda for 2026-2027
Anvisa warns of deadline for comments on agenda including review of RDC 327/2019
Submission of registrations, videos, and requests for confidentiality ends at 11:59 pm this Friday (5); item revising rules for cannabis products will be defined at the Dicol meeting on December 10
Cannabidiol grows over 70% in the pharmacy channel; Anvisa's RDC 327 review generates optimism in the sector
According to Filipe Campos, from Close-Up International, the market could expand even further with rule updates and greater medical adherence
RDC-327 and Cannabis Research: Lawyer Explains Proposal to Extend Deadline for Clinical Studies
On Deusa Cast, lawyer Larissa Meneghel details how the five-year deadline set forth in RDC-327 for clinical cannabis research works and comments on the renewal proposal under review by Anvisa
Anvisa incorporates RDC 327 rules into Ordinance 344 and formalizes veterinary prescription of cannabis
11/26/2025Anvisa's update "mirrors" the rules for controlling cannabis products directly in the list of controlled substances and defines classification for industrial inputs
Voting on RDC 327 is postponed at Anvisa; ABIQUIFI evaluates new deadline as "legitimate instrument"
The Brazilian Association of Pharmaceutical Inputs Industry trusts that the request for a view by director Thiago Campos will result in a more in-depth analysis, maintaining the expectation of concluding the regulatory framework in January 2026
Anvisa suspends review of RDC 327 after director's request for further analysis
Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence
Anvisa suspends review of RDC 327 after director's request for further analysis
Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence
Anvisa may vote on maintaining or removing the agenda item for the review of RDC 327/2019, which regulates medicinal cannabis products
The item revising RDC 327/2019 reaches a decisive week at Anvisa, and the sector awaits to know if the topic will proceed to a vote or be postponed once again
Anvisa removes the revision of RDC 327/2019 from the Collegiate Board meeting agenda
Update of the RDC included in the Regulatory Agenda 2024-2025 is expected for next year
Follow Live: Anvisa now debates review of RDC 327 and cultivation
Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow
Follow Live: Anvisa now debates revision of RDC 327 and cultivation
Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow
Anvisa to resume voting on RDC 327 in the first meeting of 2026
Norm review may limit imports via RDC 660 if there is a national equivalent; director Thiago Campos presents dissenting vote
Anvisa to decide today the future of RDC 327 in a meeting that could redefine rules for cannabis products in Brazil
Norm that regulates manufacturing, importation, prescription, and inspection may be entirely revoked and replaced by a new regulatory framework; decision will be made at the Collegiate Board meeting.
Anvisa publishes proposal to update RDC 327 redefining rules for cannabis products in Brazil
Draft presents new regulatory framework, tightens requirements for Sanitary Authorization, and prohibits manipulation of cannabis derivatives
What can change in the cannabis market after the end of sanitary authorization of RDC 327?
Free webinar will clarify Medicinal Cannabis Regulation in Brazil
Proposal to restrict Cannabis importation (RDC 660) sparks reaction in the market
Proposal in the review of RDC 327/2019 to RDC 660/2022 divides opinions and raises doubts about access and judicialization
“It is important that the compounding pharmacy has access to all cannabis inputs" argues Marco Fiaschetti, from Anfarmag
With the revision of RDC 327/2019, compounding pharmacies gain space in the discussion on medicinal cannabis
Anvisa approves new Cannabis regulation and allows compounding pharmacies
Revision of RDC 327 allows the compounding sector to produce derivatives, while individual importation by individuals remains under old rules and will be analyzed separately